ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.47) by 10.17 percent. This is a 160 percent decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $32.501 million which beat the analyst consensus estimate of $28.743 million by 13.07 percent. This is a 1.47K percent increase over sales of $2.068 million the same period last year.